Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label single-arm study of a recombinant humanized anti-IL-6 receptor monoclonal antibody in idiopathic multicentric Castleman disease
CTR20220163Phase 2Active
- Sponsor
- Beijing VDJBio Co., Ltd.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in idiopathic multicentric Castleman disease (iMCD), sponsored by Beijing VDJBio Co., Ltd.. Started May 2022; status: active.
02
Drugs
tocilizumab
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on CTR20220163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220163.